VERZONI, ELENA
VERZONI, ELENA
Universita' degli Studi di MILANO
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
2022 A. Mennitto, E. Zattarin, M. Di Maio, D. Bimbatti, U. De Giorgi, S. Buti, D. Santini, C. Casadei, M. Soraru, C. Messina, C. Mucciarini, G. Di Lorenzo, G. Roviello, C. Buttigliero, M. Stellato, P. Sepe, M. Claps, V. Guadalupi, A. Ottini, S. Pignata, F.G. De Braud, E. Verzoni, G. Procopio
Biomarker-driven immunotherapy for precision medicine in prostate cancer
2022 A. Ottini, P. Sepe, T. Beninato, M. Claps, V. Guadalupi, E. Verzoni, P. Giannatempo, G. Baciarello, F. De Braud, G. Procopio
Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients
2021 D. Rinchai, E. Verzoni, V. Huber, A. Cova, P. Squarcina, L. De Cecco, F. de Braud, R. Ratta, M. Dugo, L. Lalli, V. Vallacchi, M. Rodolfo, J. Roelands, C. Castelli, D. Chaussabel, G. Procopio, D. Bedognetti, L. Rivoltini
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
2017 P. Grassi, E. Verzoni, R. Ratta, L. Porcu, M. Prisciandaro, A. Mennitto, G. Calareso, F. de Braud, G. Procopio
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents
2017 P. Grassi, L. Doucet, P. Giglione, V. Grünwald, B. Melichar, L. Galli, U. De Giorgi, R. Sabbatini, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, L. Derosa, H. Studentova, L. Porcu, F. De Braud, C. Porta, G. Procopio
Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
2016 E. Verzoni, P. Grassi, R. Ratta, M. Niger, F. De Braud, R. Valdagni, G. Procopio
Cabozantinib in the treatment of advanced renal cell carcinoma : Design, development, and potential place in the therapy
2016 P. Grassi, E. Verzoni, R. Ratta, A. Mennitto, F. de Braud, G. Procopio
Clinical impact of Pancreatic metastases from renal cell carcinoma : A multicenter retrospective analysis
2016 P. Grassi, L. Doucet, P. Giglione, V. Grünwald, B. Melichar, L. Galli, U. De Giorgi, R. Sabbatini, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, L. Derosa, H. Studentova, M. Pacifici, J. Coppa, V. Mazzaferro, F. De Braud, C. Porta, B. Escudier, G. Procopio
Immunotherapy advances in uro-genital malignancies
2016 R. Ratta, R. Zappasodi, D. Raggi, P. Grassi, E. Verzoni, A. Necchi, M. Di Nicola, R. Salvioni, F. de Braud, G. Procopio
Treatment of elderly patients with metastatic renal cell carcinoma
2016 E. Zanardi, P. Grassi, A. Cavo, E. Verzoni, C. Maggi, F. De Braud, F. Boccardo, G. Procopio
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation
2015 D. Raggi, L. Mariani, P. Giannatempo, S. Lo Vullo, D. Giardiello, N. Nicolai, L. Piva, D. Biasoni, M. Catanzaro, T. Torelli, S. Stagni, M. Maffezzini, G. Calareso, M. Magni, M. Di Nicola, E. Verzoni, P. Grassi, G. Procopio, F. De Braud, G. Pizzocaro, R. Salvioni, A. Necchi
Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors
2015 G. Procopio, P. Grassi, I. Testa, E. Verzoni, V. Torri, R. Salvioni, R. Valdagni, F. De Braud
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
2015 P. Grassi, E. Verzoni, L. Porcu, R. Iacovelli, F. De Braud, G. Procopio
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer : a systematic review and meta-analysis
2015 R. Iacovelli, C.N. Sternberg, C. Porta, E. Verzoni, F. de Braud, B. Escudier, G. Procopio
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
2015 E. Zanardi, E. Verzoni, P. Grassi, A. Necchi, P. Giannatempo, D. Raggi, F. De Braud, G. Procopio
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma : a systematic review and meta-analysis of literature data
2015 R. Iacovelli, M. Santoni, E. Verzoni, P. Grassi, I. Testa, F. De Braud, S. Cascinu, G. Procopio
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies : overall results from a large cohort of patients
2015 G. Procopio, I. Testa, E. Verzoni, R. Iacovelli, P. Grassi, G. Galli, F. De Braud, D. Saravia, R. Salvioni
Targeted treatments in advanced renal cell carcinoma : focus on Axitinib
2014 E. Verzoni, P. Grassi, I. Testa, R. Iacovelli, P. Biondani, E. Garanzini, F. De Braud, G. Procopio
First line treatment of metastatic renal cell carcinoma : two standards with different toxicity profile
2014 R. Iacovelli, E. Verzoni, F. De Braud, G. Procopio
Study design and clinical evidence in mRCC : can we save axitinib as a first-line therapy?
2014 R. Iacovelli, E. Verzoni, F. De Braud, G. Procopio